Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent

Toxicology and Applied Pharmacology

Volumn 281, Issue 3, 2014, Pages 285-293

  Li, Jason Z ^a   Ke, Yuebin ^b   Misra, Hara P ^a   Trush, Michael A ^c   Li, Y Robert ^d,e,f   Zhu, Hong ^d   Jia, Zhenquan ^f  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NC Email:   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

Beta lapachone; Cancer cells; EPR; Mitochondrial electron transport chain; NQO1; ROS

Indexed keywords

ANTINEOPLASTIC AGENT; BETA LAPACHONE; ES 936; OXYGEN RADICAL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; ROTENONE; UNCLASSIFIED DRUG; 5-METHOXY-1,2-DIMETHYL-3-((4-NITROPHENOXY)METHYL)INDOLE-4,7-DIONE; BETA-LAPACHONE; ENZYME INHIBITOR; INDOLE DERIVATIVE; NAPHTHOQUINONE; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RNA DIRECTED DNA POLYMERASE INHIBITOR; TUMOR PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CHEMOLUMINESCENCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MEDIATOR; MELANOMA B16; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION; RESPIRATORY CHAIN; SPIN TRAPPING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; METABOLIC ACTIVATION; METABOLISM; MOUSE; NEOPLASMS; OXIDATION REDUCTION REACTION; TUMOR CELL LINE;

ACTIVATION, METABOLIC; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; ELECTRON TRANSPORT COMPLEX I; ENZYME INHIBITORS; HUMANS; INDOLEQUINONES; MICE; MITOCHONDRIA; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; NEOPLASM PROTEINS; NEOPLASMS; OXIDATION-REDUCTION; PRODRUGS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE INHIBITORS; ROTENONE;

EID: 84911874658     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.10.012     Document Type: Article

References (43)

1. Bey E.A., Bentle M.S., Reinicke K.E., Dong Y., Yang C.R., Girard L., Minna J.D., Bornmann W.G., Gao J., Boothman D.A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11832-11837.
2. Blanco E., Bey E.A., Khemtong C., Yang S.G., Setti-Guthi J., Chen H., Kessinger C.W., Carnevale K.A., Bornmann W.G., Boothman D.A., Gao J. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 2010, 70:3896-3904.
3. Brightman A.O., Wang J., Miu R.K., Sun I.L., Barr R., Crane F.L., Morre D.J. A growth factor- and hormone-stimulated NADH oxidase from rat liver plasma membrane. Biochim. Biophys. Acta 1992, 1105:109-117.
4. Dehn D.L., Siegel D., Swann E., Moody C.J., Ross D. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems. Mol. Pharmacol. 2003, 64:714-720.
5. Dong Y., Chin S.F., Blanco E., Bey E.A., Kabbani W., Xie X.J., Bornmann W.G., Boothman D.A., Gao J. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy. Clin. Cancer Res. 2009, 15:131-139.
6. Enns L., Ladiges W. Mitochondrial redox signaling and cancer invasiveness. J. Bioenerg. Biomembr. 2012, 44:635-638.
7. Fang J., Beattie D.S. Rotenone-insensitive NADH dehydrogenase is a potential source of superoxide in procyclic Trypanosoma brucei mitochondria. Mol. Biochem. Parasitol. 2002, 123:135-142.
8. Genova M.L., Bovina C., Marchetti M., Pallotti F., Tietz C., Biagini G., Pugnaloni A., Viticchi C., Gorini A., Villa R.F., Lenaz G. Decrease of rotenone inhibition is a sensitive parameter of complex I damage in brain non-synaptic mitochondria of aged rats. FEBS Lett. 1997, 410:467-469.
9. Gonzalez-Aragon D., Ariza J., Villalba J.M. Dicoumarol impairs mitochondrial electron transport and pyrimidine biosynthesis in human myeloid leukemia HL-60 cells. Biochem. Pharmacol. 2007, 73:427-439.
10. Hojo Y., Okado A., Kawazoe S., Mizutani T. Direct evidence for in vivo hydroxyl radical generation in blood of mice after acute chromium(VI) intake: electron spin resonance spin-trapping investigation. Biol. Trace Elem. Res. 2000, 76:75-84.
11. Ishii N. Role of oxidative stress from mitochondria on aging and cancer. Cornea 2007, 26:S3-S9.
12. Jia Z., Zhu H., Vitto M.J., Misra B.R., Li Y., Misra H.P. Alpha-lipoic acid potently inhibits peroxynitrite-mediated DNA strand breakage and hydroxyl radical formation: implications for the neuroprotective effects of alpha-lipoic acid. Mol. Cell. Biochem. 2009, 323:131-138.
13. Kamat J.P., Devasagayam T.P. Oxidative damage to mitochondria in normal and cancer tissues, and its modulation. Toxicology 2000, 155:73-82.
14. Kayaga J., Souberbielle B.E., Sheikh N., Morrow W.J., Scott-Taylor T., Vile R., Chong H., Dalgleish A.G. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther. 1999, 6:1475-1481.
15. Lentini A., Tabolacci C., Nardi A., Mattioli P., Provenzano B., Beninati S. Preclinical evaluation of the antineoplastic efficacy of 7-(2-hydroxyethyl)theophylline on melanoma cancer cells. Melanoma Res. 2012, 22:133-139.
16. Li Y., Trush M.A. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem. Biophys. Res. Commun. 1998, 253:295-299.
17. Li Y., Zhu H., Kuppusamy P., Roubaud V., Zweier J.L., Trush M.A. Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems. J. Biol. Chem. 1998, 273:2015-2023.
18. Li Y., Stansbury K.H., Zhu H., Trush M.A. Biochemical characterization of lucigenin (Bis-N-methylacridinium) as a chemiluminescent probe for detecting intramitochondrial superoxide anion radical production. Biochem. Biophys. Res. Commun. 1999, 262:80-87.
19. Li Y., Zhu H., Trush M.A. Detection of mitochondria-derived reactive oxygen species production by the chemilumigenic probes lucigenin and luminol. Biochim. Biophys. Acta 1999, 1428:1-12.
20. Li L.S., Bey E.A., Dong Y., Meng J., Patra B., Yan J., Xie X.J., Brekken R.A., Barnett C.C., Bornmann W.G., Gao J., Boothman D.A. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy. Clin. Cancer Res. 2011, 17:275-285.
21. Liu K.J., Miyake M., Panz T., Swartz H. Evaluation of DEPMPO as a spin trapping agent in biological systems. Free Radic. Biol. Med. 1999, 26:714-721.
22. Lu W., Hu Y., Chen G., Chen Z., Zhang H., Wang F., Feng L., Pelicano H., Wang H., Keating M.J., Liu J., McKeehan W., Luo Y., Huang P. Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol. 2012, 10:e1001326.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
24. Neuzillet C., Tijeras-Raballand A., de Mestier L., Cros J., Faivre S., Raymond E. MEK in cancer and cancer therapy. Pharmacol. Ther. 2014, 141:160-171.
25. Pardee A.B., Li Y.Z., Li C.J. Cancer therapy with beta-lapachone. Curr. Cancer Drug Targets 2002, 2:227-242.
26. Park E.J., Choi K.S., Kwon T.K. beta-Lapachone-induced reactive oxygen species (ROS) generation mediates autophagic cell death in glioma U87 MG cells. Chem. Biol. Interact. 2011, 189:37-44.
27. Pink J.J., Planchon S.M., Tagliarino C., Varnes M.E., Siegel D., Boothman D.A. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J. Biol. Chem. 2000, 275:5416-5424.
28. Ralph S.J., Rodriguez-Enriquez S., Neuzil J., Saavedra E., Moreno-Sanchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol. Aspects Med. 2010, 31:145-170.
29. Reinicke K.E., Bey E.A., Bentle M.S., Pink J.J., Ingalls S.T., Hoppel C.L., Misico R.I., Arzac G.M., Burton G., Bornmann W.G., Sutton D., Gao J., Boothman D.A. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin. Cancer Res. 2005, 11:3055-3064.
30. Rota C., Chignell C.F., Mason R.P. Evidence for free radical formation during the oxidation of 2'-7'-dichlorofluorescin to the fluorescent dye 2'-7'-dichlorofluorescein by horseradish peroxidase: possible implications for oxidative stress measurements. Free Radic. Biol. Med. 1999, 27:873-881.
31. Shao J., DeHaven J., Lamm D., Weissman D.N., Malanga C.J., Rojanasakul Y., Ma J.K. A cell-based drug delivery system for lung targeting: II. Therapeutic activities on B16-F10 melanoma in mouse lungs. Drug Deliv. 2001, 8:71-76.
32. Siegel D., Yan C., Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem. Pharmacol. 2012, 83:1033-1040.
33. Singh K.K. Mitochondria damage checkpoint, aging, and cancer. Ann. N. Y. Acad. Sci. 2006, 1067:182-190.
34. Timmins G.S., Liu K.J., Bechara E.J., Kotake Y., Swartz H.M. Trapping of free radicals with direct in vivo EPR detection: a comparison of 5,5-dimethyl-1-pyrroline-N-oxide and 5-diethoxyphosphoryl-5-methyl-1-pyrroline-N-oxide as spin traps for HO* and SO4*. Free Radic. Biol. Med. 1999, 27:329-333.
35. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
36. Tronnier M., Mitteldorf C. Treating advanced melanoma: current insights and opportunities. Cancer Manag. Res. 2014, 6:349-356.
37. Uyemura S.A., Luo S., Vieira M., Moreno S.N., Docampo R. Oxidative phosphorylation and rotenone-insensitive malate- and NADH-quinone oxidoreductases in Plasmodium yoelii yoelii mitochondria in situ. J. Biol. Chem. 2004, 279:385-393.
38. Villanueva A., Hernandez-Gea V., Llovet J.M. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:34-42.
39. Wallace D.C. Mitochondria and cancer: Warburg addressed. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:363-374.
40. Wenner C.E. Targeting mitochondria as a therapeutic target in cancer. J. Cell. Physiol. 2012, 227:450-456.
41. Wu L., Tang Z.Y., Li Y. Experimental models of hepatocellular carcinoma: developments and evolution. J. Cancer Res. Clin. Oncol. 2009, 135:969-981.
42. Zang L.Y., Misra H.P. Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Biol. Chem. 1993, 268:16504-16512.
43. Zhu H., Jia Z., Zhou K., Misra H.P., Santo A., Gabrielson K.L., Li Y. Cruciferous dithiolethione-mediated coordinated induction of total cellular and mitochondrial antioxidants and phase 2 enzymes in human primary cardiomyocytes: cytoprotection against oxidative/electrophilic stress and doxorubicin toxicity. Exp. Biol. Med. (Maywood) 2009, 234:418-429.